[急性呼吸窘迫综合征生物标志物的研究进展]

[Advances in biomarkers of ARDS].

作者信息

Fu Xuan, Lin Jinle, Zhang Wenwu, Wang Lijun

机构信息

Department of Emergency, Affiliated Baoan People's Hospital of Shenzhen, Southern Medical University, Shenzhen 518101, Guangdong, China (Fu X, Lin JL, Zhang WW); Department of Critical Care Medicine, Affiliated Baoan People's Hospital of Shenzhen, Southern Medical University, Shenzhen 518101, Guangdong, China (Wang LJ); Graduate School of Guangdong Medical University, Zhanjiang 524001, Guangdong, China (Fu X). Corresponding author: Zhang Wenwu, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jul;29(7):656-661. doi: 10.3760/cma.j.issn.2095-4352.2017.07.018.

DOI:10.3760/cma.j.issn.2095-4352.2017.07.018

PMID:28743348

Abstract

Acute respiratory distress syndrome (ARDS) is a common diseases in critical ill patients, which is an acute-onset hypoxic condition with radiographic bilateral lung infiltration. And it can be divided into two phases in pathophysiology: an acute exudative phase combining diffuse alveolar damage and lung edema followed by a later fibro proliferative phase. The early prediction and risk assessment of patients with ARDS is still very poor in the clinical. In recent years, researchers gradually focus their research on exploration of biomarkers of ARDS. The article mainly aims to sum up the development of biomarkers exploration.

摘要

急性呼吸窘迫综合征（ARDS）是危重症患者中的常见疾病，是一种急性起病的低氧状况，影像学表现为双侧肺部浸润。其病理生理学可分为两个阶段：急性渗出期合并弥漫性肺泡损伤和肺水肿，随后是后期的纤维增生期。在临床上，ARDS患者的早期预测和风险评估仍然很差。近年来，研究人员逐渐将研究重点集中在探索ARDS的生物标志物上。本文主要旨在总结生物标志物探索的进展。